Diagnostic imaging devices are used for the visualization of structural and functional patterns of organs or tissues. Contrast agents includes computed tomography (CT) contrast agents, magnetic resonance imaging (MRI) contrast agents and ultrasound contrast agents (microbubbles). GlobalData uses proprietary data and analytics to provide a comprehensive report on the contrast agents devices market, including market shares of different players within Japan. Buy the latest report here.

Smarter leaders trust GlobalData


Premium Insights Japan Contrast Agents Market Share

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

In 2021, GlobalData’s Market Model methodology determined that the leading player in the contrast agents market in Japan was Bracco Imaging followed by GE Healthcare, Bayer and Guerbet.

Computed tomography (CT) is used on patients with a high risk of colon cancer, or full-motion heart scans for patients with high risk of heart disease. It can also be used to image complex fractures, detect infarction, tumors, calcifications, hemorrhage and bone trauma and also acute and chronic changes in the lung parenchyma. This segment includes ionic iodinated CT contrast agents, non-ionic iodinated CT contrast agents and barium CT contrast agents.

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the contrast agents devices market within Japan was expected to be over $200m in 2021.

For the latest complete market share analysis of contrast agents device market in Japan, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.